Navigation Links
Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando
Date:2/22/2008

acts; a material shift in utilization within capitated agreements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company's various filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section contained in the Company's annual report on Form 10-K for the year ended December 31, 2006.

Financial and Investor Contact: John R. Potapchuk

631-501-7035

john.potapchuk@gentiva.com

Media Contact: David Fluhrer

631-501-7102

516-589-0778

david.fluhrer@gentiva.com


'/>"/>
SOURCE Gentiva Health Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Gentiva(R) Health Services Files Universal Shelf Registration Statement
2. Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007
3. Gentiva(R) Health Services to Present November 7 at CIBC Healthcare Conference in New York
4. Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco
5. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
6. Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi
7. Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011
8. Gentiva(R) Health Services Announces Fourth Quarter and Fiscal 2007 Results, and Raises 2008 Outlook
9. Penn study finds pro-death proteins required to regulate healthy immune function
10. UCLA researchers identify markers that may predict diabetes in still-healthy people
11. Air pollution linked to cardiovascular risk indices in healthy young adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... Leukemia and myeloproliferative disorders are serious and often ... 51st Annual Meeting of the American Society of ... diagnostic methods for patients suffering from acute promyelocytic ... and myelofibrosis that are based on a better ...
(Date:12/5/2009)... Solutions, an innovative new international private medical insurance plan which follows ... offering customers the flexibility to add or remove a wide range ... customers to tailor their benefits to complement those already offered in ... ...
(Date:12/4/2009)... Inc. (NYSE: CRE ) ("Care" or the "Company") ... of $0.17 per share of common stock. The dividend is ... December 14, 2009. ,, About Care Investment ... investment and finance company investing in healthcare-related real estate and commercial ...
(Date:12/4/2009)... Association of Homes and Services for the Aging (AAHSA) applauds ... Supportive Services (CLASS) provisions remain in the final health reform ... to elders, people with disabilities and their caregivers. ,, ... bill that will make it affordable to care for families ...
(Date:12/4/2009)... Calif., Dec. 4 Pamela Bowen, Chief Information Officer ... the "Chief Innovation Officer" Appy Award for transforming Crescent,s ... recipients are nominated based on their innovative usage of ... levels of customer success to their sales, marketing, partner, ...
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
... as cholera would take the heaviest toll on survivors ... camps has intensified// the spread of pneumonia, and health ... in the already devastated region. ,In the ... groups such as the World Health Organization issued statements ...
... A recent study shows , schizophrenics treated with ... risk for developing type 2 diabetes. Patients taking ... impairment of glucose effectiveness compared with patients taking ... non-obese people with schizophrenia or schizoaffective disorder who ...
... world is infected with tuberculosis every second and someone dies ... have discovered easier tests to detect this deadly disease in ... generally done with a gastric lavage. It's an invasive test ... a sputum sample. Sputum is what comes up when you ...
... for urinary tract infections also put them at risk for ... ,Researchers interviewed 242 women who were treated for kidney ... automated databases. They then compared data from these cases to ... history of kidney infections. ,Results of the study showed ...
... after a mastectomy does not reduce the long-term survival of ... had a better chance of survival than those who did ... may boost the morale and self-esteem of the patient, which ... implants could stimulate the immune system and reduce blood flow ...
... can help maintain cognitive skills in people as they ... For the study researchers reviewed data on 295 men ... and Netherlands Elderly (FINE) study. The length and intensity ... cognitive function was evaluated starting in 1990. ,Results ...
Other Medicine News:
(Date:12/4/2009)... 4 Hospira, Inc. (NYSE: HSP ), ... today announced the launch of its next-generation 50 mL ... and solutions, and now offers a complete size range ... responsible VisIV product. The launch of the 50 mL ...
(Date:12/4/2009)... developers of the AcceleDent System , which ... the availability of a new Continuing Education course ... in professional education for many industries, including medicine ... views about orthodontic treatment, a summary of treatment ...
(Date:12/4/2009)... 4 AstraZeneca (NYSE: AZN ) today ... has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release ... with Major Depressive Disorder (MDD). SEROQUEL XR is the ... to treat both major depressive disorder as adjunctive therapy ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Football Pros in October Pink Gloves 58529 1Football Pros in October Pink Gloves 58529 2Intermountain McKay Dee Hospital Center Expands Real Time Locating Solution From Versus Technology Inc 5103 1Intermountain McKay Dee Hospital Center Expands Real Time Locating Solution From Versus Technology Inc 5103 2Intermountain McKay Dee Hospital Center Expands Real Time Locating Solution From Versus Technology Inc 5103 3Breast Cancer Death Rates Continue to Drop 2 25 Annually 58525 1Breast Cancer Death Rates Continue to Drop 2 25 Annually 58525 2Breast Cancer Death Rates Continue to Drop 2 25 Annually 58525 3
... EMERYVILLE, Calif., Dec. 5 Neurobiological,Technologies, Inc. (Nasdaq: ... Holdings L.P. ("Celtic Pharma") presented interim results,for XERECEPT(R) ... Neuro-Oncology., Paul Freiman, President and Chief Executive ... continuing involvement in the development of XERECEPT,and the ...
... NEW YORK, Dec. 4 The Michael J. ... in total funding for five clinical research studies ... the Foundation,s focus on,accelerating scientific solutions that can ... initiative funds clinical research projects,with strong potential to ...
Other Medicine Technology:Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 2Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 3Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 4Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program 2Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program 3
... the Integrated Cytometry Solution offers a ... coupled with complete LIS connectivity. By ... sample undergoes - and managing the ... it delivers a progressive automated system ...
Convective Air Warming Blankets...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Inquire...
Medicine Products: